Chronic Bronchitis/Bronchiectasis, Chronic Obstructive Pulmonary Disease
Conditions
Keywords
Chest physiotherapy, Rehabilitation, Chronic respiratory diseases
Brief summary
Mechanical devices to increase the individual's bronchial hygiene are commonly used to assist patients with chronic retention of secretions. VAKÜM technology has been recently developed with the aim to improve the respiratory condition in hypersecretive patients suffering from chronic respiratory diseases. The aim of this study is to assess the clinical efficacy of VAKÜM technology in patients with hypersecretion, and chronic respiratory diseases a clinical trial has been designed. Patients with chronic respiratory diseases, hypersecretion (sputum production \>30 mL/die), and reduced cough efficiency (Peak Cough Expiratory Flow \> 150 and \< 300 L\*min-1) referred to standard pulmonary rehabilitation (PR) will be included. Study design is a single-blind multicentre randomized trial with consecutive recruitment. Following a preliminary run-in period, group comparison will be made between Intervention group using VAKÜM system (Free Aspire, MPR, Legnano-I) added to the conventional manual ELTGOL technique, and Control group using manual ELTGOL alone over 10 daily sessions. Spirometric lung volumes, respiratory muscle strength, arterial blood gases, and quality of life will be recorded in both groups pre-to-post PR. Perceived dyspnea (by VAS scale), sputum volume and characteristics (on a semi-quantitative 3-point scale) and peak expiratory air flows (PEF and PCEF) will be registered on a daily basis over the study period. Primary outcome is the change in perceived dyspnea; in order to ensure 80% power to detect a 5 point (SD 5) group difference change in the primary outcome at the end of the study period as significant at the 0.05 level, at least 42 patients per group are needed. The minimum target sample size will be then fixed at 50 patients per group. An higher and faster significant reduction of the perceived dyspnea is supposed in the Intervention group. Additional benefits among the secondary outcomes are also hypothesised in the same group.
Interventions
DEVICEVAKÜM system
15 minutes, twice a day.
OTHERconventional manual ELTGOL technique
20 minutes twice a day
Sponsors
Villa Pineta Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients with chronic respiratory diseases * hypersecretion condition(sputum production \>30 mL/die) * reduced cough efficiency (Peak Cough Expiratory Flow \> 150 and \< 300 L\*min- 1) * patients admitted to standard pulmonary rehabilitation
Exclusion criteria
* not able to use the device * concomitant cardiovascular or neoplastic diseases * utilization of Non Invasive Ventilation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in perceived dyspnea | Baseline and 10 days | Visual Analogic Scale (VAS) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in arterial blood gases exchanges | Baseline and 10 days | PaO2, PaCO2, SatO2, pH |
| Change in spirometric lung volumes | Baseline and 10 days | Static and dynamic lung volumes |
| Change in peak expiratory air flows | Baseline and 10 days | Peak Expiratory Flow (PEF), Peak Cough Expiratory Flow (PCEF) |
| Change in sputum volume and characteristics | Daily over 10 days | Volume, Density (D) and Purulence (P) (D and P assessed on a semi-quantitative 3-point scale) |
| Change in quality of life | Baseline and 10 days | Quality of life questionnaires (CAT, MRF 28) |
| Change in respiratory muscle strength | Baseline and 10 days | Maximal Expiratory Pressure (MEP), Maximal Inspiratory Pressure (MIP) |
Countries
Italy
Contacts
Primary ContactEnrico M Clini, Prof.
Outcome results
None listed